2 - Eurasanté

PROGRAM
December 2 & 3 2014 • Lille • FRANCE
A 360°
approach
to build life sciences
partnerships
www.biofit-event.com
Organized by
In cooperation with
• • • W e l c o m e t o B i o F IT 2 0 1 4 • • •
Edito
For the third time, BioFIT offers international actors in the life sciences a meeting
place between public and private stakeholders and keeps fostering the emergence
of new and innovative projects and products.
The desire to join forces has brought actors from various sectors (pharma, biotech,
medtech, IVD, animal health, technology transfer, licensing and IP professionals, academia and investors...) to discuss partnerships and bring the most relevant public
and private audience to Lille on December 2nd and 3rd. On the agenda:
• partnering activities with pre-screened one-to-one meetings
• a conference program dealing with collaborative research, new funding sources
and new approaches in technology transfer,
• a presenting technologies session offering the possibility to present key
technologies, licensing opportunities and product development.
This edition is the event not to be missed as it will gather over 1 000 attendees from
25 countries, including leading companies and professionals from pharma, biotech,
medtech, IVD but also technology transfer, licensing and IP professionals, academia
and investors.
Thanks to the quality and diversity of its participants, BioFIT looks certain to generate
this year again, excellent collaborating opportunities.
With this vote of confidence received from its attendees, the event has been taken to
the next level and we are proud to announce that BioFIT will become a yearly event.
Its 4th edition will be held in Strasbourg on December 1st & 2nd, 2015! Mark it in your
agendas and join us!
We wish you a fruitful and enjoyable two-day event full of meetings and partnership
opportunities and hope to see you again next year!
Etienne VERVAECKE,
General Commissioner of BioFIT 2014 and Eurasanté General Manager
••organizers••
Eurasanté is the economic development agency dedicated to Health, Nutrition and
Biotechnology in the Nord-Pas de Calais region. Eurasanté offers since 1996 a complete range of
services allowing to define, strengthen, finance and launch every development project on the
health and nutrition markets.
Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on today’s main health
issues, at the crossroads of Nutrition, Biotechnology, and Health.
In the Health sector, NHL focuses on developing preventive, diagnostic, and therapeutic solutions
applicable to cardiovascular and metabolic conditions, neurodegenerative diseases and
Inflammatory Bowel Diseases (IBD). Its projects in the Food sector aim at protecting health
and well-being through a safe, healthy, and sustainable diet.
In cooperation with
•
L i l l e - B i o f i t - 2 0 1 4 // 2
•
• ••summary•• •
2
Editorial
4/5
BIOFIT Agenda
6
STEERING COMMITTEE
8/9
floor plan/exhibitors list
PARTNERING ACTIVITIES
11
Plenary session
14
December 2nd
15
BIOPARTY
18
December 3rd
19
Posters & presentations
25
OUR
MISSION: THERAPEUTIC INNOVATION
GENFIT (Euronext Paris:GNFT) is a biopharmaceutical company at the
forefront of developing therapeutic and diagnostic solutions in fields of high
medical need due to a lack of suitable treatment and an increasing number of
patients worldwide.
!
GENFIT’s R&D efforts are focused on bringing new medicines to market for
patients with metabolic, inflammatory, autoimmune and fibrotic diseases,
that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the
bowel (such as inflammatory bowel disease).
!
GFT505 is GENFIT’s lead pipeline product for the treatment of NASH, a major
recognized unmet medical need.
!
!
!
Connect together:
GENFIT Headquarters - Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos France
+33 (0)3 2016 4000
www.genfit.com
!
PARTNERING
•
Big consortia: how do they work
and what are their outcomes?
L i l l e - B i o f i t - 2 0 1 4 // 4
•
Who will be funding
the maturation phase in
the future?
One-to-one
meetings
Animal Health: a key actor in
tomorrow’s innovations?
PLENARY SESSION
Pasteur Amphitheatre
New models for bridging the
gap from research to market
RUBENS ROOM
One-to-one
meetings
In partnership with
Full program p.25
Technologies & Services
Presentations
PLENARY SESSION
Accessing innovation: how to build long term partnerships?
Looking ahead: can big data hold
the key to breakthrough treatments?
7.00 • 10.00 pm bioparty
4.00 • 5.30 pm
RUBENS ROOM
3.30 • 4.00 pm coffee break
2.00 • 3.30 pm
FAIDHERBE ROOM
12.30 • 2.00 pm lunch
11.00 • 12.30 pm
PASTEUR AMPHITHEATRE
10.30 • 11.00 am coffee break
9.00 • 10.30 am
RUBENS ROOM
8.30 • 9.00 am Registration and Exhibition opening/ Welcome coffee
CONFERENCES
EGID Symposium
Eurotop Auditorium
5:00 pm: Conclusions
4:45 pm: Best poster award
4:00 pm: Brown adipose tissue and skeletal
muscle mitochondrial function as targets for
the treatment of type 2 diabetes: focus on
human intervention studies
3:30 am: Coffee break
2:45 pm: Metabolic control of nash
2:00 pm: The impact of sleep loss
and circadian misalignment on metabolism
12:30 pm: Lunch
11:45 am: Poster session
11:00 am: Islet inflammation in type 2
diabetes
10:30 am: Coffee break
9:45 am: Role of innate and adaptive
immunity in atherosclerosis
European
Genomic
Institute
for Diabetes
9:00 am: Role of gut microbiota in the
pathogenesis of diabetes
8:30 am: Registration / Welcome coffee
Meta-inflammation in diabetes
and its complications
European
Genomic
Institute
for Diabetes
hosted events
DAY ONE • d e c e m b e r 2 n d
• • • AGENDA • • •
PARTNERING
Driving innovation in Europe:
using Horizon 2020 program
l
•
Emerge & happen:
creative solutions for difficult
problems in dealmaking
L i l l e - B i o f i t - 2 0 1 4 // 5
•
Make it work and last: how to
best apply strategic alliance
management
Scouting innovation: academia
push and industry pull
RUBENS ROOM
track 3
4:00 pm: Outsourcing: the
future of the industry
2:00 pm: Meeting: Working
Group Major Accounts
4:00 pm - 5:30 pm: Do we
need a European joint diabetes
research agenda? who should
contribute to it? what should be
the goals of this joint research
agenda?
2:00 pm - 3:30 pm: Is stratified/personalized/precision
medicine one of the paradigm
on which we could ground our
collective efforts for research in
diabetes?
12:30 pm: Lunch
11:00 am - 12:30 pm:
What do you expect as a good
level of maturity of research
finding?
Too early stage for me guy!!
9:00 am - 10:30 am:
2013-2014 Breakthroughs
& innovations in the field of
diabetes
9:15 am: Open Board of
Directors
11:00 am - 12:30 pm:
Speeches and exchanges
8:30 am: Welcome coffee
Eurotop Auditorium
8:30 am: Welcome coffee
Artois Room
hosted events
DAY t w o • d e c e m b e r 3 r d
solutions for transferring innovation to market:
l Creative
TTO’s and industry’s new approaches
One-to-one meetings
One-to-one meetings
track 2
Early stage innovation: new routes to funding sources
The road less traveled: new
approaches to finance early
stage innovation
l
FAIDHERBE ROOM
New practices from the VC
industry in sourcing innovation
FAIDHERBE ROOM
The valuation process:
do all stakeholders use
the same criteria?
l
FAIDHERBE ROOM
Biotech meets Medtech:
a future perspective
track 1
Emerge, last and deliver: best practices in collaborative research
4.00 • 5.30 pm
RUBENS ROOM
3.30 • 4.00 pm coffee break
2.00 • 3.30 pm
RUBENS ROOM
12.30 • 2.00 pm lunch
11.00 • 12.30 pm
RUBENS ROOM
10.30 • 11.00 am coffee break
9.00 • 10.30 am
FAIDHERBE ROOM
8.30 • 9.00 am Registration and Exhibition opening/ Welcome coffee
CONFERENCES
• • • AGENDA • • •
• ••steering committee•• •
BioFIT 2014 is honored to receive the support of a prestigious Steering Committee composed of 19 renowned
international experts in their fields, coming from different sectors: academia, industry, clusters, service providers…
The BioFIT 2014 Steering Committee ensures the relevance of the conference program and contributes to the choice
of the speakers.
Associations,
Clusters, Investors
Industries
Academia, TTOs
Zeina ANTOUN,
Clinical Research Director,
GSK - GlaxoSmithKline (FR)
Richard BERGSTROM, Director General,
EFPIA - European Federation
of Pharmaceutical Industries and
Associations (BE)
Hervé ANSANAY,
Business Developer,
SATT Nord (FR)
Maria BOBADILLA,
Senior Director, Extending
Innovation Network, Roche (CH)
Claude-Alain CUDENNEC, General
Director, AFSSI - Association
Française des Sociétés de
Services et d’Innovation (FR)
Sami CHTOUROU,
Director of technology platforms
and innovation, LFB (FR)
Isabelle DIAZ, Research &
Biotechnology Director, LEEM / General
Secretary, ARIIS - Alliance pour
la Recherche et l’Innovation
des Industries de Santé (FR)
Ivan BAINES,
Chief Operating Officer, Max
Planck Institute of
Molecular Cell Biology
and Genetics (DE)
Garold BREIT, CEO,
Breit Ideas (USA)
Marco FIORINI, General Secretary,
Aviesan - French National
Alliance for Life Sciences
and Health (FR)
Nicolas CARBONI, President,
SATT Conectus Alsace (FR)
Gunilla EKSTROM, Vice President
Operations, Karolinska
Development (SE)
Jean-Luc CHAGNAUD,
Healthcare Business Development
Manager & IP Manager, Aquitaine
Science Transfert (FR)
Titta ROSVALL-PUPLETT, Executive
Director, EBE - European
Biopharmaceutical Enterprises
(BE)
Esther LANGE, Industry Liason
Manager, Ascenion (DE)
Maria M. FLOCCO,
Senior Director, Head Strategic
Research Partnerships Europe,
Pfizer (FR)
Guy HELIN, CEO,
Syngulon (BE)
Tomas LANDH,
Director, Strategy & Innovation
Sourcing, Diabetes Research Unit,
Novo Nordisk (DK)
Stephan LENSKY,
Vice President Strategic Transaction
& Alliances, BOEHRINGER
INGELHEIM (DE)
Anne ROY, Journalist,
AEF – Specialized news agency
(FR)
Frédéric SCAEROU,
Director, Scientific Affairs Oncology,
Ipsen Innovation (FR)
Emilie ROYERE,
Director, Eurobiomed (FR)
Mohammed CHARKI, Research &
Development Partnerships Director,
Global Project Leader Online Open
Innovation, Sanofi (FR)
BioFIT for me is one of the best places where you can meet
academics, big pharma and biotech. It’s really a unique opportunity
to meet them all in one place.
Guy HELIN, CEO, Syngulon
•
L i l l e - B i o f i t - 2 0 1 4 // 6
•
80%
© Palani Mohan
of our development
projects are biologics
9 high-potential projects
are in late-stage*
€4.8 bn
of investment in R&D
in 2013
Dean, Australia,
with multiple sclerosis
EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION
Sanofi has created an open innovation model, based on solid collaborations with its partners
and the scientific community. With this new R&D approach, Sanofi can meet its main challenges:
accelerating the transformation of scientific innovation into targeted therapeutic solutions for
patients and developing new biologic entities.
www.sanofi.com
*As of february 6, 2014
• ••floor plan•• •
F LANDRES HALL
level 8
exhibitors list
22
Poster
Area
19
E
20
21
17
18
Internet Terminals
Partnering
Desk
1
16
14
12
15
13
11
10
8
D
Coffee
Break
9
Coffee Break
Bar
7
Access to Level 11
Partnering - Lunch Area
C
Access to Pasteur
Amphitheatre
6
5
B
4
Access to Welcome Desk Eurotop Auditorium
3
European
Genomic
Institute
for Diabetes
2
A
Coffee
Break
European
Genomic
Institute
for Diabetes
1
 Partnering Desk 1
 Poster Area
Conferences Rooms
(Rubens, Faidherbe, Goya)
Preview Room
(Rembrandt)
 Breakfast, Coffee Breaks
•
L i l l e - B i o f i t - 2 0 1 4 // 8
•
AFSSI (French Association of Outsourcing
and Innovative Companies in the field of
Life Sciences)
ADVANCED BIODESIGN
BIOSIMS TECHNOLOGIES
CELL&CO BIOREPOSITORY
CILCARE
EVEDRUG
PHYLOGENE
PHYTOSAFE
POPSI CUBE
RD-BIOTECH
ROOWIN
EGID (European Genomic Institute for
Diabetes)
ILLUMINA
RAMERY
TRACE ARCHITECTES
EURASANTE & NHL CLUSTER
APTEEUS
EATCELL BIOTECH
E-ZYVEC
KIBIOS
MACOPHARMA
OCR
SMARTMABS
VAXINANO
X’PROCHEM
Réseau SATT (Tech Transfer Accelerator
Network)
SIMV (French Association of
Animal Health Industry)
4P-PHARMA
ADMESCOPE
AMYLGEN
ATLANPOLE BIOTHERAPIES
BACCINEX
CITOXLAB
CYANAGEN
ERDYN
EUROPEAN COMMISSION
HAZGO
IP PRAGMATICS
MEDICEN PARIS REGION
MERCODIA
MITA - Agency for Science, Innovation
and Technology
NORGINE
ORIGINAL PROCESS
PIERRE FABRE CDMO
PRAXIS PHARMACEUTICAL
RWS GROUP
SCREENCELL
SOLADIS
STRATICELL
A
D
C
B
E
6
20
2
10
11
1
18
17
19
9
21
8
15
4
12
22
3
5
14
13
7
16
• ••floor plan•• •
J EANNE DE F LANDRE HALL
level 11
Access to Level 8,
Flandres Hall
Catering
Partnering Booths
Poster
Area
Partnering
Desk
2
Poster
Area
Catering
 Partnering Desk 2
 Partnering Booths 1 - 44
 Sponsor Meeting Rooms 45 - 46
 Poster Area
Catering
Poster
Area
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
Internet Terminals
45
46
conception :
Luncheon
AP 
instit
210x148_Mise en page 1 20/11/14 15:57 Page1
AUJOURD’HUI
ET DEMAIN
Groupe biopharmaceutique français, le
LFB est présent dans les domaines de
l’immunologie, de l’hémostase et des
soins intensifs avec une large gamme de
médicaments dérivés du plasma qui
traitent chaque année plus de 500 000
patients atteints de pathologies graves et
parfois très rares.
VOUS POUVEZ
COMPTER SUR
LE GROUPE LFB
Afin de faire progresser la prise en charge
de certaines pathologies très graves et
améliorer également l'accessibilité de
certains traitements, le LFB développe des
programmes dans les biotechnologies avec
deux axes de développement majeurs : les
anticorps monoclonaux et les protéines
recombinantes par transgénèse.
Le LFB s'engage pour relever les défis
thérapeutiques et technologiques des
traitements de demain.
www.lfb.fr
Meet at BioFIT 2014 through
Please collect a print out of your partnering schedule at
the partnering desk which is located in the exhibition hall
and opposite the partnering booths
Network with
26,000 dealmakers
Promote
your company,
products or ideas
Gain key insights
and knowledge
YOU
Engage
in expert groups
Monitor
Screen
12,000 companies
for partnering fit
Leverage
the social web
partnering360® is an online network of life science dealmakers, providing
www.partnering360.com
• • • P ARTNERING ACTIVITIES • • •
w h o w ill y o u meet
Ascenion, AstraZeneca, Bayer, Boehringer Ingelheim, Evotec, Pfizer, Roche, Eli Lilly, Sanofi, GSK, Takeda, Max Planck
Institute, Karolinska Institute, Provendis, University of Oxford, Leiden University, King’s College London, ISIS Innovation,
Pasteur Institute, Institute Curie, Inserm Transfert, Karolinska Development, Kurma Partners, Index Ventures, GIMV, Novo
Seeds, Imperial Innovations…… and many others
28%
Investors,
Clusters, Services
43%
Pharmas,
Biotechs,
Medtechs
29%
Academics , TTO BioFIT’s partnering platform is powered by
renowned
software, which has already facilitated over
40,000 one-to-one meetings at events worldwide in the past 18 months and
is the most widely used partnering platform in the life sciences industry.
25 represented countries
Germany
Spain
Czech Republic
Ireland
France
Italy
Belgium
Poland
Netherlands
Switzerland
Portugal
Japan
Finland
Israel
Denmark
Canada
Lithuania
Sweden
Hungary
Norway
United States
United Kingdom
Luxembourg
Austria
•
L i l l e - B i o f i t - 2 0 1 4 // 1 1
•
novo nordisk
Partnering for innovation
IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES
Novo Nordisk is a world leader in diabetes
care and we have a leading position within
haemostasis management and growth
hormone therapy. We have refined our protein
competencies since 1923, and have developed
world class expertise in driving proteins from
molecule to market.
We continuously look for new partnerships.
•
DIABETES
Novel proteins or peptides affecting any
aspect of diabetes;
Novel treatments for obesity, diabetes
complications and T1D.
•
HAEMOPHILIA
Novel non-replacement therapies that
improve haemostasis.
•
TECHNOLOGY
Technologies for expressing, modifying
or producing proteins and peptides;
Formulation and drug delivery
technologies for proteins and peptides.
For more information and to contact us visit www.novonordisk.com\science\partnering
Novo Nordisk is a global healthcare company with more than 90 years of innovation
and leadership in diabetes care. The company also has leading positions within
haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees
in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s
B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on
the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Your innovation partner
At the crossroads of
Nutrition,
Biotechnology
and Health
is co-organised by NHL Cluster
• • • d e c e m b e r 2 nd• • •
PLENARY SESSION
Accessing innovation: how to build long term partnerships?
Pharma’s interest for early stage technologies is no longer news in the life sciences industry. In their quest to accessing knowledge, pharma and large biotech get more and more involved in early stage research, either by
supporting big consortia or building collaborative research partnerships directly with academia. However, what do
we know about the success of such partnerships and big consortia? Have they really worked and what were the
outcomes?
11.00 am – 12:30 pm
PASTEUR AMPHITHEATRE
Chairman
John HODGSON,
Data Editor,
Scripp Intelligence (UK)
Mike MARTIN, Senior Director,
Search & Evaluation, Takeda
(USA)
Wen Hwa LEE, Strategic Alliances Manager,
University of Oxford, Nuffield Department
of Medicine (UK)
Werner LANTHALER,
CEO, Evotec (DE)
Schwarz Holger,
External Innovation,
Merck Serono (DE)
• • • d e c e m b e r 2 nd• • •
BioFIT for me is the place to be if you
want to learn from others in tech transfer
from academia to pharma
and develop business.
Nicolas CARBONI, President,
SATT Conectus Alsace
9.00 am – 10:30 am
RUBENS ROOM
Big consortia: how do they work
and what are their outcomes?
Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around
specific questions they are all looking to find an answer to. Of course their
organization can be very different depending on the number of partners
involved and the questions addressed. But how can their outcomes be
evaluated, knowing that what comes out is non-tangible knowledge
which itself is later used in other R&D processes in order to obtain real
results? Moreover, what type of guidance is necessary in order to make
them work and obtain successful outcomes?
Chairman
Hugh LAVERTY,
Senior Scientific
Project Manager, IMI
- Innovative Medicines
Initiative (BE)
Bernd STOWASSER,
Head of Public Private Partnerships External Innovation & Science Policy,
Jacky VONDERSCHER,
President, Enyo Pharma (FR)
Sanofi (DE)
2.00 pm – 3:30 pm
Rubens Room
New models for bridging the gap
from research to market
Even though there are many collaborations put in place between pharma
and academia, the gap from academic discovery to market still exists. In
this context, we are witnessing the emergence of new initiatives like pharma-driven innovation centers, incubators and consortia. Their purpose is
to help advance drug discovery projects by accelerating the process of
innovation, but what impact will they have on the life sciences ecosystem,
including the pharma-biotech relationships?
Chairman
Garold BREIT,
Owner, Breit Ideas (USA)
Duncan HOLMES,
European Head,
Discovery Partnerships
with Academia, GSK (UK)
Bruno FRANCOIS,
Clinical Lead COMBACTE Consortium,
CHU Limoges/Inserm (FR)
Jeffrey ULMER,
Global Head of External
R&D, Novartis
Vaccines (USA)
Stefaan ALLEMEERSCH,
Director Business Development,
Centre for Drug Design and
Discovery (CD3 – Leuven) (BE)
•
Christian TIDONA,
Founder & Managing Director,
Biomed X Innovation
Center (DE)
Lille - 2014 - Biofit | 15
•
Odile PIOT-GROSJEAN,
Strasbourg R&D Site Director,
SANOFI (FR)
GSK,
A KEY PLAYER IN R&D
We have three primary areas of business
in pharmaceuticals, vaccines and
consumer healthcare. Our commercial
success depends on creating
innovative new products and making
these accessible to as many people as
possible. By achieving this, we will be
able to grow our business and provide
benefits to patients, consumers, society,
our employees and our shareholders.
Our headquarters are based in the UK,
and we have a wide geographical
reach. We have offices in more than 115
countries, major research centres in the
UK, USA, Spain, Belgium and China and
an extensive manufacturing network
with 87 sites globally.
Research is vitally important to the
success of our business, and we spent
just under £4 billion in 2012 in our search
to develop new medicines, vaccines
and innovating consumer products. We
are one of the few healthcare
companies researching medicines and
vaccines for the World Health
Organisation’s three priority diseases HIV/AIDS, tuberculosis and malaria.
As a science-led global healthcare
company we have the opportunity to
improve the health and well-being of
millions of people around the world.
Through investment in R&D and
infrastructure, and through
collaboration with other organisms, we
are innovating to address currently
unmet health needs. We are improving
access to our products, irrespective of
where people live or their ability to pay,
and we are working to control or
eliminate diseases affecting the world’s
most vulnerable people.
FR/GSKI/0011/13 – 12 septembre 2013 – © Laboratoire GlaxoSmithKline
GlaxoSmithKline is a science-led global
healthcare company that researches
and develops a broad range of
innovative medicines and brands. Our
products are used by millions of people
around the world, helping them to do
more, feel better and live longer.
• • • d e c e m b e r 2 nd• • •
2.00 pm – 3:30 pm
Faidherbe Room
Who will be funding the maturation phase
in the future?
Nicolas CARBONI,
President,
SATT Conectus
Alsace (FR)
Rémi DROLLER, Managing Partner,
Kurma Partners (FR)
In a difficult economic climate, in which venture companies prefer to
invest in lower risk or mature enterprises, finding financial resources for
project maturation seems to get ever more complicated. To whom do
TTOs and academic laboratories turn when looking for funding at this
stage and which are the best strategies to spin-off the technology so as
to ensure its success?
Tony HICKSON, Managing
Director, Technology Transfer,
Imperial Innovations (UK)
Manfred HORST, Director, Scientific
Liaison France, Ge, Eastern EU Licensing & External Research EU, Merck
Sharp & Dohme (FR)
Matthieu COUTET,
VP operation & Business Development,
AAVLIFE (FR)
BioFIT is covering key aspects of getting better at working with external partners,
identifying them and finding alternative sources of funding.
Frédéric SCAEROU, Director, Scientific Affairs Oncology, Ipsen
m
ore toda
y
fnd out
Chairman
• • • d e c e m b e r 2 nd• • •
I believe that, in this post crisis era, the importance of
partnering cannot be overstated. BioFIT has been
structured to meet the needs of the industry and
academy and research institutions. Moreover, Lille affords
a convenient user-friendly environment in which to meet
and conduct business.
Garold Breit, CEO, Breit Ideas (USA)
INVITATION
4.00 pm – 5:30 pm
RUBENS ROOM
Looking ahead: can big data hold
the key to breakthrough treatments?
In today’s healthcare system, we are able to collect large
sets of data at multiple levels. However, how can they be
transformed into knowledge? This particular aspect is
being addressed in large consortia organized by big pharmas together with biotech and IT companies. Let’s find out
how they are working and whether they can help get
concrete outcomes in terms of use of this data, of handling
it and hear about some successful outcomes.
DECEMBER 2nd 2014
7:00 pm
TRIPOSTAL
LILLE - FRANCE
A shuttle service is provided to pick you up at
Lille Grand Palais and take you to the Tripostal
Times of departure from Lille Grand Palais
6.30 pm & 6.40 pm
7.00 pm & 7.10 pm
Chairperson
Nora BENHABILLES,
Manager Program,
Health sector, CEA (FR)
Kai SIMONS, Research Group Leader and Director Emeritus,
Max Planck Institute of Cell Biology and Genetics (DE)
Philippe SANSEAU, Head Computational Biology, GSK (UK)
Jesper TEGNER, Strategic Professor of Computational Medicine Director,
Unit of Computational Medicine, Karolinska Institute (SE)
Hans CONSTANDT, CEO, Ontoforce (DE)
Exhibition
Nathalie JOURDAN, CEO, Bioptimize (FR)
•
L i l l e - B i o f i t - 2 0 1 4 // 1 8
•
Networking
Cocktail
• • • d e c e m b e r 3 rd• • •
9.00 am – 10:30 am
Rubens Room
Chairman
Garold BREIT,
Owner, Breit Ideas (USA)
Biotech meets Medtech: a future perspective
At first glance, there is a clear dividing line between medical technology
and biotechnology. In actual fact, the two areas are not always easy to
separate and the boundaries are becoming increasingly blurred. One
thing is certain – the will to join forces is there. But how do these collaborations work in reality? Let’s hear from our panelists examples of cooperation between biotech and medtech and how they perceive the future of
this sector.
Eric HALIOUA, CEO,
Promethera (BE)
Magnus BJÖRSNE, Executive
Director, AstraZeneca
BioVenture Hub (SE)
Manfred KAUER, Senior Deputy
Director, BioRegio STERN (DE)
• • • d e c e m b e r 3 rd• • •
9.00 am – 10:30 am
Faidherbe Room
l
Chairman
In order to speed up innovation, it is obvious that research alone is not
enough. It also needs to be put into use. Therefore, the EU began funding
not only the research activities, but also the commercialization of these
results. Let’s discuss in this session, what Horizon 2020 has to offer to
the technology transfer community in life sciences and how to take
advantage of these opportunities to be more efficient.
Cormac SHERIDAN,
journalist, Bioworld
(IRELAND)
Aletta DEBERNARDI, Senior
Advisor Research Funding, Leiden
University, LURIS (NL)
Driving innovation in Europe: using Horizon
2020 program
Hugh LAVERTY, Senior Scientific
Project Manager, IMI - Innovative Medicines Initiative (BE)
11.00 am – 12:30 pm
RUBENS ROOM
Philippe CUPERS, DG Research and
Innovation, Head of Neurosciences Sector,
European Commission (BE)
Philippe VERWAERDE, CEO,
Alzprotect (FR)
Emerge & happen: creative solutions
to difficult problems in dealmaking
Chairman
That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative
solutions are needed in order to finally create a mutually beneficial
partnership. During this interactive session, the panelists will discuss the
common and not so comment pitfalls in partnering and negotiations, as
well as share their experience on the different stages of negotiations,
the difficulties they ran into and the solutions they found.
Mark Bradley WILSON,
Partner, Norton Rose
Fulbright (USA)
Stephan LENSKY, Vice President Strategic
Transaction & Alliances,
Boehringer Ingelheim (DE)
11.00 am – 12:30 pm
FAIDHERBE ROOM
Jürgen WALKENHORST, Head of Life Sciences,
Provendis GmbH (DE)
l
Chairman
Pascale REDIG, Member of ASTP-Proton
Professional Development Committee, NL Senior
Sourcing Manager of Global Pharma R&D, Janssen
Pharmaceutica NV (BE)
The valuation process: do all stakeholders
use the same criteria?
Everyone knows putting a value on a technology or know-how is a
challenging process. And if the value is not correctly measured, it could
get a wrong start for the project or create difficulties in transferring the
technology. So let’s try to find out from our panel of experts how value is
measured in the life sciences field. Do all the stakeholders (TTOs, VCs,
pharma and biotech) use the same criteria?
Ivan C. BAINES, Chief
Operating Officer, Max
Planck Institute of
Molecular Cell Biology
and Genetics (DE)
Ed SALTZMAN,
President, Defined Health (USA)
•
Daniel BACH,
Managing Partner, Aravis (CH)
L i l l e - B i o f i t - 2 0 1 4 // 2 0
•
Mohammed CHARKI, Research
&Development Partnerships Director,
Sanofi (FR)
• • • d e c e m b e r 3 rd• • •
2.00 pm – 3:30 pm
RUBENS ROOM
Make it work and last: how to best apply
strategic alliance management
Chairman
The deal signature is just the beginning of a long road to travel for putting
in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both
parties, it becomes an effective and invaluable tool in the management of
the deal. Let’s discuss how to set it correctly on paper and how to identify
the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties.
Mark Bradley WILSON,
Partner, Norton Rose
Fulbright (USA)
Stephan LENSKY, Vice President Strategic
Transaction & Alliances,
Boehringer Ingelheim (DE)
Jürgen WALKENHORST, Head of Life Sciences,
Provendis GmbH (DE)
Pascale REDIG, Member of ASTP-Proton
Professional Development Committee, NL Senior
Sourcing Manager of Global Pharma R&D, Janssen
Pharmaceutica NV (BE)
BioFIT is a European independent event and it fits very well into fostering
the targets that we have in identifying innovation.
Tomas LANDH, Director, Strategy & Innovation Sourcing, Diabetes Research
Unit, Novo Nordisk
history_148x210_4c.qxd:BioFIT
17.11.2014
16:56 Uhr
Seite 1
Value through Innovation
The chemist and Nobel Prize winner Professor Heinrich Wieland
(right) was in charge of setting up the company’s first scientific
department in the 1920s.
Research for health calls for endurance. The best thing is to make an early start.
For Boehringer Ingelheim, success as a pharmaceutical company for more than 129 years has been synonymous
with introducing innovative medications. In researching and developing new therapies and dosage forms the
company invested around €2.7 billion in 2012 alone. This investment in the future has a long tradition. So it’s
no coincidence that Boehringer Ingelheim is one of the 20 most successful companies in pharmacetuicals worldwide.
Research is our driving force. More than 47,400 employees around the globe, of whom some 13,900 are in Germany,
are working to improve the prospects for healthier lives.
www.boehringer-ingelheim.com
• • • d e c e m b e r 3 rd• • •
2.00 pm – 3:30 pm
FAIDHERBE ROOM
New practices from the VC industry
in sourcing innovation
Chairman
The traditional VC industry invests in young start-ups once they evaluate
the project and the potential outcomes. However, recently they have started looking more into academia and approaching research projects in
order to detect innovation as early as possible, support it and help it get
mature. Has this trend generalized in the industry so as to speak of a
shifting environment? How are pharma and biotech seeing this and is
academia interested in the bargain?
Stephane Mottola,
Director of
International
Development, FIST (FR)
Giovanni Mariggi,
Associate, Index Ventures (CH)
Magnus BJÖRSNE, Executive Director,
AstraZeneca BioVenture Hub (SE)
4.00 pm – 5:30 pm
Faidherbe Room
Christophe VAN VAECK, Senior Investment Manager Life Sciences, GIMV (BE)
Nanna LÜNEBORG, Investment
Director, Novo Seeds (DK)
Scouting innovation: academia push
and industry pull
Chairman
Academia wants to push out knowledge and innovation on the one hand
and the industry is looking to pull it in and bring it to market on the other
hand. However simple this might seem, when putting it into practice there
are many challenges to overcome. Let’s find out which are the new models that pharma and biotech are using in scouting innovation and how
are TTOs better packaging the offer in order to find more matches with
the demand?
Georg KÄÄB, Cluster
Manager Bavarian Biotech
Cluster, Bio-M Corporate
Communications,
BioM Biotech Cluster
Development
Development GmbH (DE)
Adam STOTEN, Deputy Head of Technology
Transfer, ISIS Innovation (UK)
•
Raj MEHTA, Business Development
Executive, Cancer Research
Technology (UK)
L i l l e - B i o f i t - 2 0 1 4 // 2 2
•
Jane Atkins Director, Global Licensing & Business Development (CH)
— © Dan Tentler / Getty Images
Caroline,
still as style-conscious
as ever...
… and Ipsen played an important part in keeping it that way.
For Caroline, who suffers from a debilitating disease,
challenging her friends to a quad bike race is priceless.
Each year, Ipsen invests 20% of its sales in R&D to further its expertise in three specialty care
areas: urology-oncology, endocrinology and neurology. The company also has a significant
presence in primary care. In more than 100 countries, Ipsen employees devote their energy and
skills to developing innovative therapeutic solutions for debilitating diseases and improving the
quality of life of patients. www.ipsen.com
• • • d e c e m b e r 3 rd• • •
l
4.00 pm – 5:30 pm
Rubens Room
Chairman
Claire Skentelbery,
Secretary General,
European Biotechnology
Network (BE)
The road less traveled: new approaches
to finance early stage innovation
Many experts believe the era of the traditional venture-backed financing
model to fund drug development has passed. If this is true, what other
models can companies explore for driving innovation? In this session we
will discuss some of the alternative paths to funding drug discovery and
development, including new collaborative and business approaches, in a
challenging economic environment
Axel KALINOWSKI, Manager
Continental Europe, London
Stock Exchange (UK)
Souleymane Galadima,
Director of Development,
WiSEED (FR)
Lucia Robert, Director,
MATWIN (FR)
Condensed innovation
10 years of research in just one cubic centimetre.
Our innovations help millions of people by
alleviating their suffering and improving their quality of life.
We give them hope.
210x148_ProgHeft_Kapsel_e.indd 1
17.11.14 14:00
• • • P o s t e r s & p r e s e n tat i o n s • • •
Goya ROOM
December 2nd
from 2:00 pm – 5:45 pm
Come and listen to 10 min pitches
of innovative technologies, products and services
ABUNDNZ
Ultrasensitive assay for bioanalytical studies with innovative medicines
2:00 pm
CAPSULAE
Microencapsulation as a solution for therapeutic applications
2:15 pm
CYANAGEN
Novel fluorescent IR-marker for monitoring the kidney function
2:30 pm
VITAMFERO
VitamFero : a novel generation of veterinary live attenuated
prophylactic treatments
2:45 pm
DELPHI GENETICS
The Staby® technology: No antibiotics and higher yields in recombinant
proteins, pDNA productions and antibody development
3:00 pm
IMSTAR
Innovative Image Cytometry Solutions for biomarkers identification
and validation in research and cyto-pathology
3:15 pm
INMOTE MEDTECH
Inmote MedTech: Easy, secure and consistent documentation
in woundcare
4:00 pm
JAGIELLONIAN UNI
Novel antiviral agents against coronaviruses
4:15 pm
OCR
OCR – The OneHealth Company
4:30 pm
QUINTEN
Quinten: Expert in strategic data leveraging
4:45 pm
2BIND
Fast and quantitative analysis of molecular interactions using
the MicroScale Thermophoresis (MST)
5:00 pm
3M
3M Emphaze aex hybrid purifier: purification to the next level
5:15 pm
4P PHARMA
Translating science to product: General methodolodgy for addressing
technological and financial Challenges
5:30 pm
•
L i l l e - B i o f i t - 2 0 1 4 // 2 5
•
Discover more technologies and
services at the Poster Area - Espace
Jeanne de Flandre - Level 8
4P PHARMA, AMYLGEN, KALLISTEM, OCR, QUANTACELL, QUINTEN, VOXCAN, 3M, CAPSULAE,
CATALENT, CYANAGEN, ORIGINAL
PROCESS, VITAMFERO, 2BIND,
ABUNDNZ, INRA, SOLADIS, CAPITOL EUROPE, DELPHI GENETICS,
IMSTAR, INMOTE MEDTECH, JAGIELLONIAN UNI, SEPPIC,
SUSSEX UNI
The Poster & Presentation session
is organized in partnership
with the LEEM
www.biofit-event.com
They support us
Sponsors
Gold
silver
bronze
contributing
Farbe/colour:
PANTONE 288 CV
tium de
sor
on orisation
al
hémat
ique
T
V
C
Supporters
CMYK
Blue: 100/15/0/35
Orange: 0/75/90/0
Biotechnologie-Industrie-Organisation Deutschland e. V.
FEBiotec
F e d e r a c i ó n E s p a ñ o l a d e B i o t e c n ó l o g o s
media supporters
institutional
partners
Event Management:
Conference Program:
Registration & Sponsorship:
Event Venue
Marion SIGIER
+33 (0)3 59 39 01 84
msigier@eurasante.com
Ramona PIRV
+33 (0)3 59 39 01 84
rpirv@eurasante.com
Margaux SATOLA
+33 (0)3 59 39 01 82
msatola@eurasante.com
Lille Grand Palais
1 bd des Cités Unies
F-59777 Lille-Euralille
FRANCE
SAVE
THE
DATE
NEW
LOCATION
2015
4
th
Printed on recycled paper
Photos credits : © Sven Hoppe/Fotolia - Eurasante
EDITION
Want to learn all about BioFIT 2015 ?
Register online !
WWW.BIOFIT-EVENT.COM/2015
Organized by
Supported by